257 related articles for article (PubMed ID: 19246275)
21. [2-deoxy-D-glucose modified supermagnetic iron oxide nanoparticles enhance the contrasting effect on MRI of human lung adenocarcinoma A549 tumor in nude mice].
Shan X; Yuan D; Xiong F; Gu N; Wang P
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):85-91. PubMed ID: 24796454
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo magnetic resonance imaging with chlorotoxin-conjugated superparamagnetic nanoprobes for targeting hepatocarcinoma.
Chen Z; Xiao EH; Kang Z; Zeng WB; Tan HL; Li HB; Bian DJ; Shang QL
Oncol Rep; 2016 May; 35(5):3059-67. PubMed ID: 26934940
[TBL] [Abstract][Full Text] [Related]
23. [Transhepatic arterial embolization with superparamagnetic iron oxide and lipiodol for the treatment of VX2 tumor in rabbits].
Liang Q; Deng L; Feng Z; Liu X; Ding J; Hu P; Wang W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Nov; 42(11):1248-1256. PubMed ID: 29187650
[TBL] [Abstract][Full Text] [Related]
24. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging.
Kim YK; Kim CS; Kwak HS; Lee JM
J Magn Reson Imaging; 2004 Nov; 20(5):826-37. PubMed ID: 15503325
[TBL] [Abstract][Full Text] [Related]
25. Superparamagnetic iron oxide for liver imaging. Comparison among three different preparations.
Bach-Gansmo T; Fahlvik AK; Ericsson A; Hemmingsson A
Invest Radiol; 1994 Mar; 29(3):339-44. PubMed ID: 8175309
[TBL] [Abstract][Full Text] [Related]
26. In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: detection and monitoring at 3T.
Ittrich H; Lange C; Tögel F; Zander AR; Dahnke H; Westenfelder C; Adam G; Nolte-Ernsting C
J Magn Reson Imaging; 2007 Jun; 25(6):1179-91. PubMed ID: 17520738
[TBL] [Abstract][Full Text] [Related]
27. The value of fast and ultrafast T2-weighted MR imaging sequences in hepatic enhancement with ferumoxides: comparison with conventional spin-echo sequence.
Abe Y; Yamashita Y; Namimoto T; Tang Y; Takahashi M
Radiat Med; 2000; 18(2):97-105. PubMed ID: 10888042
[TBL] [Abstract][Full Text] [Related]
28. Persistent T2*-hypointensity of the liver parenchyma after irradiation to the SPIO-accumulated liver: An imaging marker for responses to radiotherapy in hepatic malignancies.
Furuta T; Yamaguchi M; Minami M; Ohtomo K; Fujii H
J Magn Reson Imaging; 2017 Jan; 45(1):303-312. PubMed ID: 27373786
[TBL] [Abstract][Full Text] [Related]
29. Double-contrast MRI (DC-MRI) in the study of the cirrhotic liver: utility of administering Gd-DTPA as a complement to examinations in which SPIO liver uptake and distribution alterations (SPIO-LUDA) are present and in the identification and characterisation of focal lesions.
Macarini L; Marini S; Milillo P; Vinci R; Ettorre GC
Radiol Med; 2006 Dec; 111(8):1087-102. PubMed ID: 17171525
[TBL] [Abstract][Full Text] [Related]
30. The mechanism of ring enhancement in hepatocellular carcinoma on superparamagnetic iron oxide-enhanced T1-weighted images: an investigation into peritumoral Kupffer cells.
Tanimoto A; Wakabayashi G; Shinmoto H; Okuda S; Kuribayashi S; Mukai M
J Magn Reson Imaging; 2005 Mar; 21(3):230-6. PubMed ID: 15723373
[TBL] [Abstract][Full Text] [Related]
31. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration.
Grandin C; Van Beers BE; Robert A; Gigot JF; Geubel A; Pringot J
J Comput Assist Tomogr; 1995; 19(3):412-8. PubMed ID: 7790551
[TBL] [Abstract][Full Text] [Related]
32. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
[TBL] [Abstract][Full Text] [Related]
33. Superparamagnetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function.
Tanimoto A; Yuasa Y; Shinmoto H; Jinzaki M; Imai Y; Okuda S; Kuribayashi S
Radiology; 2002 Mar; 222(3):661-6. PubMed ID: 11867782
[TBL] [Abstract][Full Text] [Related]
34. Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions.
Namkung S; Zech CJ; Helmberger T; Reiser MF; Schoenberg SO
J Magn Reson Imaging; 2007 Apr; 25(4):755-65. PubMed ID: 17335040
[TBL] [Abstract][Full Text] [Related]
35. [Magnetic resonance imaging of hepatic focal lesions: dynamic contrastographic evaluation with gadolinium versus reticulo-endothelial hepato-specific contrast media].
Di Cesare E; Cariello G; Barile A; Sabatini M; Michelini O; Erriquez D; Masciocchi C
Radiol Med; 2000 Oct; 100(4):245-50. PubMed ID: 11155451
[TBL] [Abstract][Full Text] [Related]
36. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions.
Winter TC; Freeny PC; Nghiem HV; Mack LA; Patten RM; Thomas CR; Elliott S
AJR Am J Roentgenol; 1993 Dec; 161(6):1191-8. PubMed ID: 8249724
[TBL] [Abstract][Full Text] [Related]
37. The role of SPIO-enhanced MRI in the detection of malignant liver lesions.
Savranoglu P; Obuz F; Karasu S; Coker A; Secil M; Sagol O; Igci E; Dicle O; Astarcioglu I
Clin Imaging; 2006; 30(6):377-81. PubMed ID: 17101405
[TBL] [Abstract][Full Text] [Related]
38. Characterization of focal hepatic lesions with SPIO-enhanced MRI.
Zheng WW; Zhou KR; Chen ZW; Shen JZ; Chen CZ; Zhang SJ
World J Gastroenterol; 2002 Feb; 8(1):82-6. PubMed ID: 11833077
[TBL] [Abstract][Full Text] [Related]
39. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.
Yoo HJ; Lee JM; Lee JY; Kim SH; Kim SJ; Han JK; Choi BI
Invest Radiol; 2009 Dec; 44(12):800-7. PubMed ID: 19838119
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images.
Korenaga K; Korenaga M; Furukawa M; Yamasaki T; Sakaida I
J Gastroenterol; 2009; 44(7):733-41. PubMed ID: 19387532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
